Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: M05BA06

Ibandronic acid Accord(ibandronic acid)

Wounds and Injuries;Breast Diseases;Neoplastic Processes;Calcium Metabolism Disorders;Water-Electrolyte Imbalance

Marketing Authorisation Holder: Accord Healthcare S.L.U.

EMA Authorisation: 18/11/2012

INN: ibandronic acid

Indication

Ibandronic acid is indicated in adults for Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Treatment of tumour induced hypercalcaemia with or without metastases. Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ibandronic acid Accord — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.